Principal Investigator/Program Director (Last, first, middle): 
patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose - " 
interleuidn-2 alone. N Engl J Med 316:889-897. 1987. 
1 1 . Chou T, Chang AE, and Shu S: Generation of therapeutic T lymphocytes from tumor-bearing mice by in 
vitro sensitization: culture requirements and characterization of immunologic specificity J Immunol 
140:2453-2461, 1988. " 
12. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, 
Seipp CA, Simon P, Simpson CG, and Rosenberg SA: Immunotherapy of patients with advanced cancer 
using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. One 6-839- 
853, 1988. 
13. Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE: Cellular basis of immunologic interactions in 
adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J. Immunol 
141:1047-1053,1988. 
14. Chou T, Bertera S, Chang AE, Shu S: Adoptive immunotherapy of microscopic and advanced visceral 
metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J. Immunol 
141:1775-1781, 1988. 
15. Stephenson KR, Perry-Lalley D, Griffith KD, Shu S, Chang AE: Development of antitumor reactivity in 
regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts. Surgery 
105:523-528, 1989. 
16. Chang AE, Perry-Lalley DM, Shu S: Distinct immunologic specificity of tumor regression mediated by 
effector cells isolated from immunized and tumor-bearing mice. Cell. Immunol . 120:419-429, 1989. 
17. Chang, A.E., Rosenberg, S.A.: Overview of interleukin-2 as an immunotherapeutic agent. Sem. Surg. 
One. 5:385-390, 1989. 
18. Sakai, K., Chang, A.E., and Shu, S.: Effector phenotype and immunologic specificity of T cell 
mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity. Cell. Immunol . 
129:241-255, 1990. 
19. Sakai K, Chang AE, Shu S: Phenotype analyses and cellular mechanisms of pre-effector T lymphocyte 
response to a progressive syngeneic murine sarcoma. Cancer Res . 50:4371-4376, 1990. 
20. Vander Woude DL, Wagner PD, Shu S, and Chang AE: Enhanced antitumor reactivity of tumor- 
sensitized T cells by interferon-alpha. Arch. Surg . 106:307-313, 1991. 
21. Yoshizawa H, Chang AE, and Shu S: Specific adoptive immunotherapy mediated by tumor-draining 
lymph node cells sequentially activated with anti-CD3 and EL-2. J. Immuno. 147:729-737, 1991. 
22. Yoshizawa H, Sakai K, Chang AE, and Shu S: Activation by anti-CD3 of tumor-draining lymph node 
cells for specific adoptive immunotherapy. Cell. Immunol. 134:473-479, 1991. 
23. Sondak VK, Wagner PD, Shu S, and Chang AE: Suppressive effects of visceral tumor on the generation 
of antitumor T cells for adoptive immunotherapy. Ajch. Surg . 126:442-446, 1991. 
24. Yoshizawa H, Chang AE, and Shu S: Cellular interactions in effector cell generation and tumor 
regression mediated by anti-CD3/IL-2 activated tumor-draining lymph node cells. Cancer Res. 52:1 129- 
1136, 1992. 
25. Chang AE, and Shu S: Immunotherapy with sensitized lymphocytes. Cancer Invest. 10(5):357-369, 
1992. 
26. Geiger JD, Wagner PD, Shu S, and Chang AE: A novel role for autologous tumor cell vaccination in the 
immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg. One. 1:199-208, 1992. 
27. Wagner PD, Shu S, and Chang AE: Divergent effects of TNFain the adoptive immunotherapy of a 
murine sarcoma. J. Surg. Res . 53:152-157, 1992. 
28. Nabel GJ, Chang AE, Nabel EG, Plautz GE, Fox BA, Huang L, and Shu S: Immunotherapy of 
malignancy by in vivo gene transfer into tumors. Human Gene Therapy 3:399-410, 1992. 
29. Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, and Shu S: Clinical observations on 
adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. 
Cancer Res. 53:1043-1050. 1993. 
30. Geiger JD, Wagner PD, Cameron MJ, Shu S, and Chang AE: Generation of T cells reactive to the 
poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. I 
Immunother. 13:153-165, 1993. 
31. Nabel GJ, Nabel E, Yang Z, Fox B, Plautz G, Gao X, Huang L, Shu S, Gordon D, and Chang AE: 
Direct gene transfer for the treatment of human disease-A trial of immunotherapy for melanoma. Proc. 
Natl Acad. Sci. (in press). 
PHS 398 (Rev. 10/88) Page 9/8/93 4:27 PM 
* Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 5a, 5b. 
[ 812 ] 
Recombinant DNA Research, Volume 
18 
